Zusammenfassung
Die Alzheimer-Krankheit (AK) ist ein progredient verlaufender histopathologisch definierter neurodegenerativer Prozess, dessen klinische Manifestation sich in das Stadium der leichten kognitiven Beeinträchtigung (LKB) sowie in das Stadium der Demenz unterteilen lässt. Nach ICD-10 ist die Diagnose der AK an die Manifestation des Demenzsyndroms gebunden. Auch die Indikation medikamentöser Therapien ist auf das Demenzstadium beschränkt. Die diagnostischen Methoden haben sich in den vergangene Jahren dramatisch verbessert. Dazu gehören die Darstellung der Atrophie des medialen Temporallappens im MRT, die Messung von τ- und β-Amyloid im Liquor, die Visualisierung kortikaler Stoffwechseldefizite in der Positronenemissionstomographie (PET) mit [18F]-Fluoro-2-desoxy-D-Glucose (FDG) sowie die sich abzeichnende Möglichkeit, Amyloidablagerungen im Gehirn mithilfe von PET-Liganden in vivo sichtbar zu machen. Mithilfe dieser Verfahren kann heute die Diagnose AK mit großer Sicherheit bereits im Stadium der LKB gestellt werden. Aus dem damit verbundenen Auseinanderdriften von diagnostischen Möglichkeiten und therapeutischen Optionen ergeben sich zahlreiche neue Fragen bezüglich der möglichen Vor- und Nachteile der Frühdiagnose für den einzelnen Patienten. Wesentlich scheint es zu sein, die Patienten in die Entscheidung zur Frühdiagnostik mit einzubeziehen und die Begrenztheit bzw. das Fehlen therapeutischer Optionen im Stadium der LKB bei AK klarzustellen.
Summary
Alzheimer’s disease (AD) is a histopathologically defined progressive neurodegenerative disorder. Its clinical manifestation can be subdivided into the stage of mild cognitive impairment (MCI) and the stage of dementia. According to ICD-10 the diagnosis of AD can only be made in the stage of dementia. The indication for anti-dementia drugs is restricted to the stage of dementia in AD, too. Diagnostic tools to detect AD have improved considerably in recent years. They include the MRI findings of atrophy of the medial temporal lobe, cerebrospinal fluid (CSF) biomarkers β-amyloid and τ, the visualisation of metabolic deficits on positron emission tomography (PET) using [18F]-fluoro-2-deoxy-D-glucose (FDG) and the emerging possibility to demonstrate amyloid deposits in vivo using PET ligands. The application of these methods allows the diagnosis of AD to be established already in the stage of MCI. While diagnostic methods improve and enable us to make the diagnosis of AD very early, there is no such progress in the development of treatment options. Early diagnosis of AD appears to have benefits and drawbacks. It is most important to include the patient in the decision on early diagnosis and to make clear that there is a lack of therapeutic options if the diagnosis is positive.
Literatur
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4. Aufl. Washington D.C.
Arzneimittelkomission der deutschen Ärzteschaft (2004) Empfehlungen zur Therapie der Demenz http://www.akdae.de/Arzneimitteltherapie/TE/Archiv/Demenz.pdf (Zugriff am 05.05.2010)
Bamford C, Lamont S, Eccles M et al (2004) Disclosing a diagnosis of dementia: a systematic review. Int J Geriatr Psychiatry 19:151–169
Barnes DE, Yaffe K, Belfor N et al (2009) Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial. Alzheimer Dis Assoc Disord 23:205–210
Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613
Botwinick J, Storandt M, Berg L (1986) A longitudinal, behavioral study of senile dementia of the Alzheimer type. Arch Neurol 43:1124–1127
Bouwman FH, Schoonenboom SN, Flier WM van der et al (2007) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28:1070–1074
Braskie MN, Klunder AD, Hayashi KM et al (2008) Plaque and tangle imaging and cognition in normal aging and Alzheimer’s disease. Neurobiol Aging
Brayne C, Richardson K, Matthews FE et al (2009) Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75 s cohort (CC75C) study. J Alzheimer Dis 18:645–658
Cummings JL, Mega M, Gray K et al (1994) The neuropsychiatric inventory – comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314
Davis RN, Massman PJ, Doody RS (2001) Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord 15:1–9
DeCarli C, Frisoni GB, Clark CM et al (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64:108–115
Dekosky ST, Ikonomovic MD, Styren SD et al (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145–155
Deutsche Gesellschaft für Psychotherapie und Nervenheilkunde (2009) S3-Leitlinie „Demenzen“ (Kurzversion) http://media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-leitlinie-demenz-kf.pdf
Drzezga A, Lautenschlager N, Siebner H et al (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113
Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746
Ebly EM, Hogan DB, Parhad IM (1995) Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 52:612–619
Folstein MF, Folstein SE, Mchugh PR (1975) Mini-Mental State – practical method for grading cognitive state of patients for clinician. J Psychiatr Res 12:189–198
Gertz HJ, Wolf H, Arendt T (2002) Vascular dementia. Nervenarzt 73:393–404
Gertz HJ, Xuereb J, Huppert F et al (1998) Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer’s disease. Acta Neuropathol 95:154–158
Gertz HJ, Xuereb JH, Huppert FA et al (1996) The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample. Eur Arch Psychiatry Clin Neurosci 246:132–136
Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27:570–575
Grober E, Hall C, McGinn M et al (2008) Neuropsychological strategies for detecting early dementia. J Int Neuropsychol Soc 14:130–142
Grober E, Sanders AE, Hall C, Lipton RB (2010) Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord
Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 110:1129–1134
Hughes CP, Berg L, Danziger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–1645
Iliffe S, Robinson L, Brayne C et al (2009) Primary care and dementia: 1. diagnosis, screening and disclosure. Int J Geriatr Psychiatry 24:895–901
Ittner LM, Ke YD, Delerue F et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142:387–397
Ivemeyer D, Zerfaß R (2002) Demenztests in der Praxis: Ein Wegweiser. Urban & Fischer, München Jena
Jack CR Jr., Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128
Kinsella GJ, Mullaly E, Rand E et al (2009) Early intervention for mild cognitive impairment: a randomised controlled trial. J Neurol Neurosurg Psychiatry 80:730–736
Klunk WE, Engler H, Nordberg A et al (2003) Imaging the pathology of Alzheimer’s disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 13:781–789, ix
KRAL VA (1962) Senescent forgetfulness: benign and malignant. Can Med Assoc J 86:257–260
Kurz A, Lautenschlager NT (2010) Cognitive interventions for cognitively impaired elderly individuals in a clinical perspective (eingereicht)
Kurz AF, Lautenschlager NT (2010) The concept of dementia: retain, reframe, rename or replace? Int Psychogeriatr 22:37–42
Leicht H, Gertz HJ (2009) Methods for assessing impaired insight in Alzheimer’s disease – a critical review. 58–66
Luck T, Busse A, Hensel A et al (2008) Mild cognitive impairment and development of dementia. Psychiatr Prax 35:331–336
Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393
Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486
Mosconi L, De SS, Li Y et al (2006) Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med Mol Imaging 33:210–221
Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6:78–87
Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754–760
Olazaran J, Muniz R, Reisberg B et al (2004) Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology 63:2348–2353
OLG Köln (1988) Unzulässigkeit einer Diagnoseaufklärung. Medizinrecht, S 184–185
Petersen RC, Stevens JC, Ganguli M et al (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133–1142
Rogaev EI, Sherrington R, Rogaeva EA et al (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376:775–778
Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94–9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–135
Rozzini L, Chilovi BV, Bertoletti E et al (2006) Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 21:550–555
Sarazin M, Berr C, De RJ et al (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 69:1859–1867
Saxton J, Lopez OL, Ratcliff G et al (2004) Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63:2341–2347
Schonknecht P, Pantel J, Kaiser E et al (2007) Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci Lett 416:39–42
Serrano-Pozo A, William CM, Ferrer I et al (2010) Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133:1312–1327
Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413
Sherrington R, Rogaev EI, Liang Yet al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760
Shin J, Lee SY, Kim SH et al (2008) Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. Neuroimage 43:236–244
Storandt M, Grant EA, Miller JP, Morris JC (2006) Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67:467–473
Tabert MH, Manly JJ, Liu X et al (2006) Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 63:916–924
Thalmann B, Monsch AU, Schneitter M et al (2007) Die CERAD Neuropsychologische Testbatterie: Ein gemeinsames minimales Instrumentarium zur Demenzabklärung. Memory Clinic, Universitätsspital Basel
Thambisetty M, Simmons A, Velayudhan L et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67:739–748
Troyer AK, Murphy KJ, Anderson ND et al (2008) Changing everyday memory behaviour in amnestic mild cognitive impairment: a randomised controlled trial. Neuropsychol Rehabil 18:65–88
Unverzagt FW, Kasten L, Johnson KE et al (2007) Effect of memory impairment on training outcomes in ACTIVE. J Int Neuropsychol Soc 13:953–960
Waldemar G, Phung KT, Burns A et al (2007) Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 22:47–54
Walhovd KB, Fjell AM, Brewer J et al (2010) Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol 31:347–354
WHO (2007) International Classification of Diseases 10th Revision (ICD-10). http://www.who.int/classifications/apps/icd/icd10online/.
Wischik C, Staff R (2009) Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13:367–369
Zaudig M, Mittelhammer J, Hiller W et al (1991) SIDAM – s structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. Psychol Med 21:225–236
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gertz, HJ., Kurz, A. Diagnose ohne Therapie. Nervenarzt 82, 1151–1159 (2011). https://doi.org/10.1007/s00115-010-3213-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-010-3213-3